

**AMENDMENT TO**  
**RULES COMMITTEE PRINT 116-60**  
**OFFERED BY MR. LAMALFA OF CALIFORNIA**

At the end of division F (before the short title), insert the following:

1       SEC. \_\_\_\_\_. (a) None of the funds made available by  
2 this Act may be used for—

3           (1) any gender reassignment medical interven-  
4 tion;

5           (2) any health benefits coverage that includes  
6 coverage of gender reassignment medical interven-  
7 tions; or

8           (3) any health care service furnished by or in  
9 a health care facility operated or owned by the Fed-  
10 eral Government, or by a physician or other indi-  
11 vidual employed by the Federal Government to pro-  
12 vide health care services within the scope of the phy-  
13 sician's or individual's employment, that includes  
14 gender reassignment medical intervention.

15       (b) The prohibition described in subsection (a) shall  
16 not apply with respect to the following individuals:

17           (1) An individual with external biological sex charac-  
18 teristics that are irresolvably ambiguous, such as those

1 born with 46 XX chromosomes with virilization, 46 XY  
2 chromosomes with undervirilization, or having both ovar-  
3 ian and testicular tissue.

4 (2) An individual with respect to whom a physician  
5 has determined through genetic or biochemical testing  
6 that the individual does not have normal sex chromosome  
7 structure, sex steroid hormone production, or sex steroid  
8 hormone action for a biological male or female.

9 (c) For purposes of this section, the term “gender  
10 reassignment medical intervention” means—

11 (1) performing a surgery that sterilizes an indi-  
12 vidual, including castration, vasectomy,  
13 hysterectomy, oophorectomy, metoidioplasty,  
14 penectomy, phalloplasty, and vaginoplasty, to change  
15 the body of such individual to correspond to a sex  
16 that is discordant with biological sex;

17 (2) performing a mastectomy on an individual  
18 for the purpose described in paragraph (1); and

19 (3) administering or supplying to an individual  
20 medications for the purpose described in paragraph  
21 (1), including—

22 (A) GnRH agonists or other puberty-block-  
23 ing drugs to stop or delay normal puberty;

1                   (B) testosterone or other androgens to bio-  
2           logical females at doses that are  
3           supraphysiologic to the female sex; and

4                   (C) estrogen to biological males at doses  
5           that are supraphysiologic to the male sex.

